Q1 2026 Invivyd Inc Earnings Call Transcript
Key Points
- Invivyd Inc (IVVD) has accelerated recruitment for its pivotal program, exceeding internal expectations.
- The company has increased its government affairs activity, receiving positive feedback from policymakers.
- Invivyd Inc (IVVD) confirmed virus neutralization of its medicines against the Omicron BA.3.2 variant.
- The company reported continued growth in monoclonal antibody revenues, contrasting with declining COVID-19 vaccine revenues.
- Invivyd Inc (IVVD) is expanding its early discovery pipeline to include antibodies for measles, mumps, rubella, Lyme disease, and other pathogens.
- The company had to slow recruitment due to a lull in COVID-19 and respiratory disease burden.
- There is uncertainty about the inclusion of the 30-minute post-administration monitoring time for VYD2311 in the product label.
- The company faces challenges in educating the public and policymakers about the benefits of monoclonal antibodies.
- Invivyd Inc (IVVD) is experiencing high clinical spending, impacting its financials.
- There is a risk of declining vaccine utilization due to public perception of vaccine reactogenicity.
Good day, and thank you for standing by. Welcome to the Invivyd first quarter 2026 earnings conference call. (Operator Instructions) Please note that today's conference is being recorded. I will now hand the conference over to your speaker host for today, Katie Falzone, Senior Vice President of Finance. Please go ahead.
Thank you, Livia. A short while ago, we issued a press release announcing our Q1 2026 financial results and recent business highlights. That press release and the slides that are being used on today's webcast can be found in the Investors section of the Invivyd website under the Press Release and Events and Presentation sections, respectively.
Today's discussion will be led by Marc Elia, Chairman of Invivyd's Board of Directors. He is joined by Dr. Michael Mina, Chief Medical Officer, Dr. Robert Allen, Chief Scientific Officer, Tim Lee, Chief Commercial Officer, and Bill Duke, Chief Financial Officer.
During today's discussion, we will be making
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
